iCAD
ICAD develops and delivers cancer detection and radiation therapy solutions, and services that enable clinicians to find and treat cancers.
Launch date
Employees
Market cap
AUD61.9m
Enterprise valuation
AUD31m (Public information from Sep 2024)
Share price
$1.56 ICAD
Nashua New Hampshire (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 29.7m | 33.6m | 27.9m | 17.3m | 19.2m | 23.9m | 29.0m |
% growth | (5 %) | 13 % | (17 %) | (38 %) | 11 % | 24 % | 21 % |
EBITDA | (16.2m) | (10.2m) | (13.2m) | (6.6m) | (6.0m) | - | - |
% EBITDA margin | (54 %) | (30 %) | (47 %) | (38 %) | (31 %) | - | - |
Profit | (17.6m) | (11.2m) | (13.7m) | (4.8m) | (7.1m) | (5.8m) | (2.6m) |
% profit margin | (59 %) | (33 %) | (49 %) | (28 %) | (37 %) | (24 %) | (9 %) |
EV / revenue | 10.2x | 5.4x | 1.7x | 2.7x | 2.2x | 1.8x | 1.5x |
EV / EBITDA | -18.8x | -17.8x | -3.5x | -7.1x | -7.1x | - | - |
R&D budget | 8.1m | 9.2m | 8.6m | 5.2m | - | - | - |
R&D % of revenue | 27 % | 27 % | 31 % | 30 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
N/A | $15.0m | Post IPO Debt | |
N/A | $12.5m | Post IPO Equity | |
N/A | $22.0m | Post IPO Equity | |
Total Funding | - |